Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study

被引：23
作者：
Dreno, Brigitte
Ascierto, Paolo Antonio
McArthur, Grant A.
Atkinson, Victoria
Liszkay, Gabriella
Di Giacomo, Anna Maria
Mandala, Mario
Demidov, Lev V.
Stroyakovskiy, Daniil
Thomas, Luc
De la Cruz-Merino, Luis
Dutriaux, Caroline
Garbe, Claus
Rooney, Isabelle Anne
Hsu, Jessie J.
Park, Erica
Ribas, Antoni
Larkin, James M. G.
机构：
[1] CHU Nantes, Dept Dermatol, Nantes, France
[2] Natl Tumour Inst Fdn G Pascal, Naples, Italy
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Univ Melbourne, Melbourne, Vic, Australia
[5] Univ Queensland, Brisbane, Qld, Australia
[6] Natl Inst Oncol, Budapest, Hungary
[7] Univ Hosp Siena, Ctr Immuno Oncol, Siena, Italy
[8] Papa Giovanni XXIII Canc Ctr Hosp, Bergamo, Italy
[9] N N Blokhin Russian Canc Res Ctr, Moscow, Russia
[10] Moscow City Oncol Hosp 62, Moscow, Russia
[11] Lyon Univ, Cancerol Inst Lyon Civ Hosp, Canc Res Ctr Lyon, Pierre Benite, France
[12] Hosp Univ Virgen Macarena, Seville, Spain
[13] Bordeaux Hosp, Dermatol & Pediat Dermatol Dept, Bordeaux, France
[14] Eberhard Karls Univ Tubingen, Tubingen, Germany
[15] Genentech Inc, San Francisco, CA USA
[16] Univ Calif Los Angeles, Los Angeles, CA USA
[17] Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
[18] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9522
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9522
引用
收藏
页数：2
相关论文
共 27 条
[1]   5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study [J].
Ascierto, Paolo A. ;
Dreno, Brigitte ;
Larkin, James ;
Ribas, Antoni ;
Liszkay, Gabriella ;
Maio, Michele ;
Mandala, Mario ;
Demidov, Lev ;
Stroyakovskiy, Daniil ;
Thomas, Luc ;
de la Cruz-Merino, Luis ;
Atkinson, Victoria ;
Dutriaux, Caroline ;
Garbe, Claus ;
Hsu, Jessie ;
Jones, Surai ;
Li, Haocheng ;
McKenna, Edward ;
Voulgari, Athina ;
McArthur, Grant A. .
CLINICAL CANCER RESEARCH, 2021, 27 (19) :5225-5235
[2]   Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma [J].
Larkin, James M. G. ;
Del Vecchio, Michele ;
Ascierto, Paolo Antonio ;
Schachter, Jacob ;
Garbe, Claus ;
Neyns, Bart ;
Mandala, Mario ;
Lorigan, Paul ;
Miller, Wilson H. ;
Guminski, Alexander David ;
Berking, Carola ;
Rutkowski, Piotr ;
Queirolo, Paola ;
Hauschild, Axel ;
Arance, Ana Maria ;
Brown, Michael Paul ;
Mitchell, Lada ;
Veronese, Maria Luisa ;
Blank, Christian U. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[3]   Safety and Efficacy of Vemurafenib in Patients with BRAFV600 Mutation-Positive Metastatic Melanoma Previously Treated with Ipilimumab: a Subgroup Analysis from a Vemurafenib Expanded Access Program [J].
Hamid, O. ;
Flaherty, L. ;
Day, B. -M ;
Abhyankar, S. ;
Hainsworth, J. .
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 :54-55
[4]   Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study. [J].
Dummer, Reinhard ;
Queirolo, Paola ;
Guijarro, Ana Maria Abajo ;
Hu, Youyou ;
Wang, Dao ;
Azevedo, Sergio Jobim ;
Robert, Caroline ;
Ascierto, Paolo Antonio ;
Chiarion-Sileni, Vanna ;
Pronzato, Paolo ;
Spagnolo, Francesco ;
Mujika, Karmele ;
Liszkay, Gabriella ;
Merino, Luis De la Cruz ;
Tawbi, Hussein A. .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5]   Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study [J].
McArthur, Grant A. ;
Chapman, Paul B. ;
Robert, Caroline ;
Larkin, James ;
Haanen, John B. ;
Dummer, Reinhard ;
Ribas, Antoni ;
Hogg, David ;
Hamid, Omid ;
Ascierto, Paolo A. ;
Garbe, Claus ;
Testori, Alessandro ;
Maio, Michele ;
Lorigan, Paul ;
Lebbe, Celeste ;
Jouary, Thomas ;
Schadendorf, Dirk ;
O'Day, Stephen J. ;
Kirkwood, John M. ;
Eggermont, Alexander M. ;
Dreno, Brigitte ;
Sosman, Jefferey A. ;
Flaherty, Keith T. ;
Yin, Ming ;
Caro, Ivor ;
Cheng, Suzanne ;
Trunzer, Kerstin ;
Hauschild, Axel .
LANCET ONCOLOGY, 2014, 15 (03) :323-332
[6]   Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive melanoma with central nervous system (CNS) metastases (mets): Final results and exploratory biomarker analysis from the phase 2 TRICOTEL study [J].
Dummer, Reinhard ;
Levesque, Mitchell ;
Bellini, Elisa ;
Chen, Marissa ;
Hu, Youyou ;
Wong, Tiffany ;
Stassen, Katja ;
Duhard, Pauline ;
Yan, Yibing ;
Tawbi, Hussein A. .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7]   Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis [J].
Blank, Christian U. ;
Larkin, James ;
Arance, Ana M. ;
Hauschild, Axel ;
Queirolo, Paola ;
Del Vecchio, Michele ;
Ascierto, Paolo A. ;
Krajsova, Ivana ;
Schachter, Jacob ;
Neyns, Bart ;
Garbe, Claus ;
Sileni, Vanna Chiarion ;
Mandala, Mario ;
Gogas, Helen ;
Espinosa, Enrique ;
Hospers, Geke A. P. ;
Miller, Wilson H., Jr. ;
Robson, Susan ;
Makrutzki, Martina ;
Antic, Vladan ;
Brown, Michael P. .
EUROPEAN JOURNAL OF CANCER, 2017, 79 :176-184
[8]   Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial [J].
McArthur, A. ;
Stroyakovskiy, Daniil ;
Gogas, Helen ;
Robert, Caroline ;
Lewis, Karl ;
Protsenko, Svetlana ;
Pereira, Rodrigo ;
Eigentler, Thomas ;
Rutkowski, Piotr ;
Demidov, Lev ;
Manikhas, Georgy Moiseevich ;
Yan, Yibing ;
Huang, K. C. ;
Uyei, Anne ;
McNally, Virgina ;
Gutzmer, Ralf ;
Ascierto, Paolo .
CANCER RESEARCH, 2020, 80 (16)
[9]   Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study [J].
Si, Lu ;
Zhang, Xiaoshi ;
Xu, Zhen ;
Jiang, Qiudi ;
Bu, Lilian ;
Wang, Xuan ;
Mao, Lili ;
Zhang, Weijiang ;
Richie, Nicole ;
Guo, Jun .
BMC CANCER, 2018, 18
[10]   Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study [J].
Chapman, P. B. ;
Robert, C. ;
Larkin, J. ;
Haanen, J. B. ;
Ribas, A. ;
Hogg, D. ;
Hamid, O. ;
Ascierto, P. A. ;
Testori, A. ;
Lorigan, P. C. ;
Dummer, R. ;
Sosman, J. A. ;
Flaherty, K. T. ;
Chang, I. ;
Coleman, S. ;
Caro, I. ;
Hauschild, A. ;
McArthur, G. A. .
ANNALS OF ONCOLOGY, 2017, 28 (10) :2581-2587
123